NEW YORK, NY — Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule oncology approaches with immunotherapeutic effects, today announced that the pre-specified efficacy requirement of its Phase 2 study of PT-112 for recurrent thymoma has been exceeded. Patients with recurrent thymoma have limited options for standard of care treatment, and...
Latest News
MELBOURNE, Australia — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced that the Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer...
Garden City, NY — ProPhase Labs Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs,...
UNIONDALE, NY — ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its study, “Assessing Risk of Progression in Barrett’s Esophagus Using a Mass-Spectrometry-Based Proteomic Panel,” has been published online in Clinical and Translational Gastroenterology, the official journal of the American College of Gastroenterology (ACG). The publication presents full clinical validation data supporting BE-Smart,...
Patients with moderate or severe hemophilia A can benefit from early prophylactic antihemophilic factor (recombinant) (rAHF), according to an interim analysis presented at the 2021 British Society for Haematology annual meeting. The international AHEAD study is a 6 year non-interventional, prospective trial looking at joint health in patients receiving prophylactic...
The use of intravenous immunoglobulin (IVIG) may provide benefit against infections in subgroups of patients with multiple myeloma (MM), according to a retrospective, single-center crossover study that compared rates of infection in patients with MM during observation compared with those receiving IVIG. The study results were published in Clinical Lymphoma, Myeloma...
LEIDEN, Netherlands & CAMBRIDGE, Mass. — ProQR Therapeutics NV, a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced a collaboration with the Rett Syndrome Research Trust (RSRT) that will focus on the design and development of editing oligonucleotides...
LEIDEN, Netherlands & CAMBRIDGE, Mass. – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQR’s...
LEIDEN, Netherlands & CAMBRIDGE, Mass. – ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and...
WELLESLEY HILLS, Mass. — Joseph F. Finn, Jr., C.P.A. (“Finn”) announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three blood-borne cancers: chronic lymphocytic leukemia (“CLL”), multiple myeloma (“MM”) and diffuse large B cell lymphoma (“DLBCL”). In clinical studies, GCS-100 has demonstrated activity as a single...